Sommetrics, a company providing products and services to improve sleep quality, has added Raymond Huggenberger to its board of directors and Randall Whitfield to its advisory board.
With more than 20 years of operational experience in the healthcare industry, Huggenberger is the former CEO of Inogen, a medical technology company that develops, manufactures, and markets oxygen concentrators. Prior to joining Inogen, he held executive leadership roles with leading companies including Sunrise Medical and the healthcare division of TA Triumph Adler. At Sunrise Medical, Huggenberger held several positions spanning more than a decade, including president and chief operating officer from 2002 to 2004.
“With its disruptive technology and passionate team, Sommetrics is poised to dramatically and positively change the way sleep apnea and sedation-related apnea are treated,” says Huggenberger in a release. “I’m looking forward to being a part of this journey and contributing to the company’s commercialization.”
Whitfield joins Sommetrics’ advisory board with nearly 4 decades of business experience and more than 15 years in the respiratory industry. He led various business groups at Philips Healthcare including hospital respiratory care, emergency care and resuscitation, anesthesia care, and therapeutic temperature management. Whitfield was also the president of the critical care business unit at Respironics, as well as the president of Puritan Bennett.
“This is an exceptionally exciting time in Sommetrics’ growth. The healthcare industry is in need of a substantial shift in sleep apnea therapy, and I believe Sommetrics’ technology will precisely address this need,” says Whitfield. “I’m pleased to join Sommetrics’ world renowned group of experts.”
Earlier this year, Sommetrics’ aerSleep received Health Canada approval—allowing it to be marketed in Canada. The company also recently announced a distribution agreement with Smiths Medical for aerFree, Sommetrics’ acute care device that aids in keeping a patient’s upper airway open during mild to moderate sedation.
